Brind.
  1. Bristol Myers' drug Opdivo is identified as a key component of the company's growth portfolio.

Ono Pharmaceutical and Bristol-Myers Squibb collaborated to develop the drug Opdivo.

1 report, 1 independent Updated Tue 00:00
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Ono Pharmaceutical and Bristol-Myers Squibb collaborated to develop the drug Opdivo.

Who's involved

What this event is mainly about
Ono PharmaceuticalBristol-Myers Squibb

Keep exploring

Part of

Bristol Myers' drug Opdivo is identified as a key component of the company's growth portfolio. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped